NCT00758069已完成2 期
Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
- 主要终点
- Change From Baseline in 24-hour Weighted Mean Plasma Glucose
研究概览
简要总结
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients Have Type 2 Diabetes Mellitus On Diet/Exercise Therapy
排除标准
- •Patients Have Type 1 Diabetes Mellitus
研究组 & 干预措施
2
Experimental
Sitagliptin 100 mg
干预措施: sitagliptin phosphate (Drug)
结局指标
主要结局
Change From Baseline in 24-hour Weighted Mean Plasma Glucose
时间窗: Baseline and Week 4
Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0.
次要结局
- Change From Baseline in Plasma Glucose(Baseline and Week 4)
研究者
相似试验
已完成
3 期
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)Chronic Renal InsufficiencyDiabetes Mellitus, Type 2NCT00095056Merck Sharp & Dohme LLC91
已完成
3 期
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)Type 2 Diabetes MellitusNCT00372060Merck Sharp & Dohme LLC134
已完成
3 期
Sitagliptin Added-on to Insulin Study (0431-051)Type 2 Diabetes MellitusNCT00395343Merck Sharp & Dohme LLC641
已完成
3 期
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)Type 2 Diabetes MellitusNCT00350779Merck Sharp & Dohme LLC262
已完成
3 期
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)Diabetes Mellitus, Non-Insulin-DependentNCT00411554Merck Sharp & Dohme LLC319